Covered recipient · General Payments record
ALISSA V ACKELSON
Allopathic & Osteopathic Physicians Internal Medicine Infectious Disease
General Payments · PY2020–2022
$37,152.20
- Reported across 22 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2022 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $13,346.69 | 7 |
| Education | $25.47 | 2 |
By paying entity
PY2022 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | $13,346.69 | 7 |
| Shionogi Inc | $25.47 | 2 |
By program year
All program years on this page · sorted by year
Payment records · PY2022 (9)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Shionogi Inc | $12.27 | 02/23/2022 | Education | Undisputed | 01/23/2026 | 950954459 | CMS |
| Shionogi Inc | $13.20 | 02/23/2022 | Education | Undisputed | 01/23/2026 | 950954461 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $1,906.67 | 01/11/2022 | Consulting Fee | Undisputed | 01/23/2026 | 955579323 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $1,906.67 | 02/07/2022 | Consulting Fee | Undisputed | 01/23/2026 | 955579327 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $1,906.67 | 03/08/2022 | Consulting Fee | Undisputed | 01/23/2026 | 955579331 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $1,906.67 | 04/09/2022 | Consulting Fee | Undisputed | 01/23/2026 | 955579335 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $1,906.67 | 05/09/2022 | Consulting Fee | Undisputed | 01/23/2026 | 955579339 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $1,906.67 | 06/06/2022 | Consulting Fee | Undisputed | 01/23/2026 | 955579343 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $1,906.67 | 07/13/2022 | Consulting Fee | Undisputed | 01/23/2026 | 955579347 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2020, 2021, 2022
- Source files
- Dataset page · Bulk file · PY2020 , PY2021 , PY2022
- Generated from
- OP_DTL_GNRL_PGYR2022_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.